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Edited by Robert BaroukiAbstract In this study, we demonstrate that pretreatment with
aspirin inhibits GH-induced insulin resistance. GH was observed
to lead to serine phosphorylation of IRS-1, a phenomenon which
was reversed by aspirin in liver, muscle and WAT in parallel with
a reduction in JNK activity. In addition, our data show an
impairment of insulin activation in the IR/IRS/PI(3)kinase path-
way and a reduction in IRS-1 protein levels in rats treated with
GH, which was also reversed in the animals pretreated with aspi-
rin. Overall, these results provide new insights into the mecha-
nism of GH-induced insulin resistance.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Insulin stimulation initiates intracellular signaling by acti-
vation of insulin receptor (IR) tyrosine kinase and tyrosine
phosphorylation of endogenous substrates [1]. IR substrate
(IRS)-1/2 are major IR substrates that recruit various Src
homology 2 (SH2) domain – containing signaling molecules,
including the p85 regulatory subunit of phosphatidylinositol
3-kinase (PI 3-kinase) [2,3]. In insulin target cells, such as adi-
pose and skeletal muscle cells, insulin-stimulated glucose
transport is mostly achieved by the translocation of GLUT4
from the intracellular storage pool to the plasma membrane
(PM), which is mediated by a PI 3-kinase-dependent pathway
[4,5].
The chronic eﬀects of growth hormone (GH) are considered
to be anti-insulin, and they include increased blood glucose
concentrations, decreased peripheral insulin sensitivity despite
higher levels of insulin secretion, decreased insulin-stimulated
glucose uptake in muscle, increased hepatic glucose production
and stimulation of lipolysis [6]. In vivo studies indicate that
chronic administration of GH in rats induced insulin resis-
tance, which was accompanied by decreases in insulin-stimu-Abbreviations:GH, growth hormone; IR, insulin receptor; IRS, insulin
receptor substrate; JNK, c-jun N terminal kinase; PI 3-kinase, phos-
phatidylinositol 3-kinase; WAT, white adipose tissue
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phosphorylation of IRS-1/2 in skeletal muscle [7]. However,
the mechanism that modulates IR and IRS-1 in chronic GH-
treated rats has not yet been described.
Many mechanisms may contribute to the deregulation of the
insulin-signaling pathway, including serine phosphorylation of
IRS proteins by protein kinases such as c-jun N terminal ki-
nase (JNK) [8–10]. JNK is a member of the MAP kinase fam-
ily [11] and can be activated by TNFa [12] and IL 1b [13]. In
addition, JNK might serve as a feedback inhibitor during insu-
lin stimulation [9]. There are three JNK isoforms described,
named JNK1, 2 and 3 [14], of which JNK1 is the most in-
volved in the pathophysiology of obesity and insulin resistance
[12]. JNK activation induces inhibitory serine 307 (Ser307)
phosphorylation of IRS-1, as shown in previous studies
[9,15]. Ser307 is located next to the phosphotyrosine-binding
(PTB) domain in IRS-1 and its phosphorylation inhibits the
interaction of the PTB domain with the phosphorylated
NPEY motif in the activated insulin receptor, causing insulin
resistance [15].
Recent evidence indicates that aspirin improves insulin sen-
sitivity, probably by reducing serine phosphorylation of IRS-
1. This may be the consequence of reduced JNK and/or
IKKb serine kinase activity, induced by aspirin. Since JNK
is stimulated by GH and inhibited by aspirin [16–18], the
current study was designed to investigate the molecular
events of GH-associated insulin resistance, and aspirin was
used to test the inﬂuence of GH on the IRS-1 serine phos-
phorylation. Results demonstrate that aspirin is able to par-
tially inhibit GH-induced insulin resistance and IRS-1 serine
phosphorylation.2. Materials and methods
2.1. Animals
We studied six-week-old male Wistar rats. All experiments involving
animals were in accordance with the guidelines of the Brazilian College
for Animal Experimentation (COBEA) and were approved by the eth-
ics committee at the University of Campinas. Room temperature was
maintained between 21 and 23 C, rats were subjected to a standard
light–dark cycle (06:00–18:00/18:00–06:00) and provided with standard
rodent chow and water ad libitum.
2.2. GH and aspirin pretreatment
Rats were treated with growth hormone (GH; 1 mg/kg sc) twice dai-
ly over 2.5 days. Starting at 12:00 h on the day before the experiment,
salicylate (42 mg/kg; Sigma Chemical Co., St. Louis, Missouri, USA)
or saline (for the control and GH groups, matching volume) was fedation of European Biochemical Societies.
R.R. Prattali et al. / FEBS Letters 579 (2005) 3152–3158 3153using oral gavage at 6-h intervals (i.e., at 12:00, 18:00, and 24:00 h).
The food was removed from the cage at 17:00 h for the overnight fast-
ing of animals.
2.3. Protein analysis by immunoblotting
Rats were anaesthetized by intraperitoneal injection of sodium thio-
pental (50 mg/kgbodyweight) and the experimentswere performedafter
the loss of corneal and pedal reﬂexes. The abdominal cavity was opened,
the cava vein was exposed, and 0.5 ml of normal saline (0.9%NaCl) with
or without 106 mol/l of insulin was injected. Liver, muscle and WAT
were removed after 30, 90 and 90 s, respectively, minced coarsely and
homogenized immediately in the solubilization buﬀer containing
100 mM Tris (pH 7.6), 1% Triton X-100, 150 mMNaCl, 0.1 mg aproti-
nin, 35 mg PMSF/ml, 10 mMNa3VO4, 100 mMNaF, 10 mMNa4P2O7,
and 4 mMEDTA, using a politron PTA 20S generator operated atmax-
imum speed for 30 s and clariﬁed by centrifugation. Equal amounts of
protein were used for immunoprecipitation followed by Western blot
analysis with the indicated antibodies and 125I-Protein A. 125I-Protein
Abound to the antiphosphotyrosine and anti-peptide antibodieswas de-
tected by autoradiography using preﬂashed Kodak XAR ﬁlm with Cro-
nex Lightning Plus intensifying screens at 80 C for 12–48 h. Band
intensities were quantitated by optical densitometry (Hoefer Scientiﬁc
Instruments, San Francisco; model GS 300) of the developed autoradio-
graphs. The antibodies against IR (sc-711), IRS-1 (sc-559), IRS-2 (sc-
8299), SOCS3 (sc-9023), phospho-JNK (sc-6254), phosphor-JUN
(sc-822) and anti-phosphotyrosine (sc-508) were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA). Antibodies against the p85 sub-
unit of PI 3-kinase and IRS-1 phosphorylated at Ser307 were from
Upstate Biotechnology (Lake Placid, NY).
2.4. Insulin tolerance test
Rats were fasted overnight and submitted to an intravenous insulin
tolerance test (IVITT; 1 U/kg body weight of insulin, i.v.) and samples
for blood glucose measurements were collected at 0 (basal), 4, 8,12,
and 16 min after injection. Rats were anaesthetized, then 40 ll of blood
were collected from their tails and blood glucose concentration was
measured by the glucose oxidase method. The rate constant for plasma
glucose disappearance (Kitt) was then calculated using the formula
0.693/(t1/2). The plasma glucose t1/2 was calculated from the slope of
the least squares analysis of the plasma glucose concentrations during
the linear phase of decline [19].
2.5. Statistical analysis
Where appropriate, the results were expressed as the mean ± S.E.M.
accompanied by the indicated number of rats used in experiments.
Comparisons among groups were made using parametric 2-way ANO-
VA, where F ratios were signiﬁcant, further comparisons were made
using Newman–Keuls test.Fig. 1. IR tyrosine phosphorylation and protein levels in liver, muscle and
stimulated tyrosine phosphorylation of IRS-1. Liver, muscle and WAT from
immunoprecipitated with anti-IR antibodies and blotted with anti-phospho
(mean ± S.E.M., n = 6) are expressed relative to control. *P < 0.05 insulin co3. Results
3.1. Metabolic characteristics
GH treated animals were more insulin resistant than the
control rats, as expressed by their lower plasma glucose disap-
pearance rates measured by the insulin tolerance test (Kitt Con-
trol: 4.65 ± 0.45%/min vs. GH: 1.84 ± 0.22%/min; P < 0.05).
Aspirin partially reversed the GH-induced insulin resistance
(Kitt GH: 1.84 ± 0.22%/min vs. GH + Aspirin: 3.91 ± 0.18%/
min; P < 0.05).3.2. In vivo eﬀect of insulin on tyrosine phosphorylation of IR in
the liver, muscle and WAT
The eﬀect of in vivo intravenous insulin infusion on IR tyro-
sine phosphorylation was examined in the liver, muscle and
WAT of controls, GH and GH plus aspirin pretreated rats.
Fragments of tissues from insulin or vehicle-treated rats were
submitted to immunoprecipitation with anti-IR antibody and
then blotted with anti-phosphotyrosine antibody. In the liver,
IR tyrosine phosphorylation was observed to increase in con-
trol animals by 8.5-fold following insulin administration com-
pared with a 2.9-fold increase in the liver of GH-pretreated
rats and a 6.7-fold increase in the liver of GH-plus-aspirin-
pretreated rats (Fig. 1A). In the muscle, IR tyrosine phosphor-
ylation increased by 9.3-fold in control animals following
insulin administration, compared with a 4.2-fold increase in
the muscle of GH-pretreated rats and a 9.9-fold increase in
the muscle of GH-plus-aspirin-pretreated rats (Fig. 1B). In
WAT, IR tyrosine phosphorylation increased by 8.5-fold in
control animals following insulin administration, compared
with a 4.4-fold increase in the WAT of GH-pretreated rats
and 9.2-fold increase in the WAT of GH-plus-aspirin-pre-
treated rats (Fig. 1C). The protein concentration of IR in liver,
muscle and WAT did not change with GH or aspirin treatment
(Fig. 1. lower panels).3.3. In vivo eﬀect of insulin on tyrosine phosphorylation of IRS-1
in the liver, muscle and WAT
In the liver, IRS-1 tyrosine phosphorylation and IRS-1/PI-
3 kinase association were observed to increase in controlWAT of rats pretreated with vehicle, GH or GH + aspirin. Insulin-
rats treated with insulin or vehicle were lysed and tissue extracts were
tyrosine antibody (pY – upper panel) or anti-IR (lower panel). Data
ntrol vs. insulin GH. # P < 0.05 insulin GH vs. insulin GH + aspirin.
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tion, respectively, compared with 3.1- and 3.2-fold increases
in the liver of GH-pretreated rats and 9.1- and 7.0-fold in-
creases in the liver of GH-plus-aspirin-pretreated rats (Fig.
2A). In the muscle, IRS-1 tyrosine phosphorylation and
IRS-1/PI 3-kinase association increased by 7.9- and 8.1-fold,
respectively, in control animals following insulin administra-
tion compared with 3.6- and 2.5-fold increases in the muscle
of GH-pretreated rats and 7.9- and 6.4-fold increases in the
muscle of GH-plus-aspirin-pretreated rats (Fig. 2B). In
WAT, IRS-1 tyrosine phosphorylation and IRS-1/PI 3-ki-
nase association increased by 7.9- and 8.2-fold, respectively,
in control animals following insulin administration compared
with 3.1- and 2.6-fold increases in the WAT of GH-pre-
treated rats and 7.6- and 5.7-fold increases in the WAT from
GH plus aspirin pretreated rats (Fig. 2C). In addition, the
IRS-1 protein concentrations were reduced in liver, muscle
and WAT from GH-treated rats and pretreatment with aspi-Fig. 2. IRS-1 tyrosine phosphorylation, IRS-1/PI 3-kinase association and
vehicle, GH or GH + aspirin. Insulin-stimulated tyrosine phosphorylation of
for 90 s were lysed and tissue extracts were immunoprecipitated with anti-anti
upper panel), anti-PI 3-K (middle panel) or anti-IRS-1 (lower panel). Data (m
control vs. insulin GH. # P < 0.05 insulin GH vs. insulin GH + aspirin.rin partially restored IRS-1 protein levels (Fig. 2 lower pan-
els). With respect to IRS-1 phosphorylation and PI 3-K
association, when the data were corrected for the change
in the number of IRS-1 molecules, the results showed a
slight (but not statistically signiﬁcant) decrease in the appar-
ent stoichiometry of IRS-1 tyrosine phosphorylation and PI
3-K association (data not shown).
3.4. In vivo eﬀect of insulin on tyrosine phosphorylation of IRS-2
in the liver, muscle and WAT
In the liver, IRS-2 tyrosine phosphorylation and IRS-2/PI-
3 kinase association were observed to increase in control ani-
mals by 7.3- and 9.6-fold following insulin administration,
respectively, compared with 2.3- and 3.1-fold increases in
the liver from GH pretreated rats and 5.5- and 6.7-fold
increases in the liver of GH-plus-aspirin pretreated rats
(Fig. 3A). In the muscle, IRS-2 tyrosine phosphorylation
and IRS-2/PI 3-kinase association increased by 10.6- andIRS-1 protein levels in liver, muscle and WAT of rats pretreated with
IRS-1. Liver, muscle and WAT from rats treated with insulin or vehicle
-IRS-1 antibody and blotted with anti-phosphotyrosine antibody (pY –
ean ± S.E.M., n = 6) are expressed relative to control. *P < 0.05 insulin
Fig. 3. IRS-2 tyrosine phosphorylation, IRS-2/PI 3-kinase association and IRS-2 protein levels in liver, muscle and WAT of rats pretreated with
vehicle, GH or GH + aspirin. Insulin-stimulated tyrosine phosphorylation of IRS-1. Liver, muscle and WAT from rats treated with insulin or vehicle
for 90 s were lysed and tissue extracts were immunoprecipitated with anti-anti-IRS-2 antibody and blotted with anti-phosphotyrosine antibody (pY –
upper panel), anti-PI 3-K (middle panel) or anti-IRS-2 (lower panel). Data (means ± S.E.M., n = 6) are expressed relative to control. *P < 0.05
insulin control vs. insulin GH. #P < 0.05 insulin GH vs. insulin GH + aspirin.
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administration compared with 5.6- and 2.5-fold increases in
the muscle of GH-pretreated rats and 8.3- and 7.6-fold in-
creases in the muscle of GH-plus-aspirin pretreated rats
(Fig. 3B). In WAT, IRS-2 tyrosine phosphorylation and
IRS-2/PI 3-kinase association increased by 6.6- and 7.6-fold,
respectively, in control animals following insulin administra-
tion compared with 2.6- and 2.3-fold increases in the WAT
of GH-pretreated rats and 7.6- and 6.7-fold increases in
the WAT of GH-plus-aspirin-pretreated rats (Fig. 3C). The
protein concentration of IRS-2 in the liver, muscle and
WAT did not change with GH or aspirin treatment (Fig.
1. lower panels).Fig. 4. Blockade of GH-induced IRS-1 serine phosphorylation and IRS-1 pro
or GH plus vehicle or aspirin, liver (A), muscle (B), or WAT (C) were then
blotted with phosphoserine-speciﬁc IRS-1 antibodies (upper panel) and with
group is shown (mean ± S.E.M., n = 5).3.5. Aspirin inhibits Ser307 phosphorylation of IRS-1 in
GH-treated animals
Among the serine residues that become phosphorylated in
response to risk factors of insulin resistance, Ser307 has been
studied extensively and Ser307 phosphorylation has become a
molecular indicator of insulin resistance [9,12,15,20]. It has
been reported that aspirin could inhibit IRS-1 serine phos-
phorylation [21], but the eﬀect of aspirin on GH-induced
IRS-1 serine phosphorylation has not been identiﬁed. To ad-
dress this issue, we tested Ser307 phosphorylation in liver, mus-
cle and white adipose tissue (WAT). As shown in Fig. 4 (upper
panels), there was a signiﬁcant increase in IRS-1 serine phos-
phorylation in rats pre-treated with GH, which was associatedtein levels reduction by aspirin. Rats were pretreated with either vehicle
lysed and the proteins were separated by SDS–PAGE on 8% gels and
IRS-1 antibodies (lower panel). A representative Western blot of each
Fig. 5. Blockade of GH-induced JNK and JUN phosphorylation, but not SOCS 3 by aspirin. Rats were pretreated with either vehicle or GH plus
vehicle or aspirin, liver (A), muscle (B), or WAT (C) were then lysed and the proteins were separated by SDS–PAGE on 12% gels and blotted with
phosphoserine-speciﬁc JNK antibodies (upper panel), with phosphoserine-speciﬁc JUN antibodies (middle panel) and SOCS 3 (lower panel). A
representative Western blot of each group is shown (mean ± S.E.M., n = 5).
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liver muscle and WAT. In animals pretreated simultaneously
with aspirin and GH, aspirin was found to reduce Ser307 phos-
phorylation by 70–85% and increase IRS-1 protein levels
greatly in all tissues.3.6. Aspirin inhibits JNK activity in GH-treated animals
JNK activation was determined by monitoring phosphoryla-
tion of JNK (Thr183 and Tyr185) and c-Jun (Ser63), which is a
substrate of JNK. JNK phosphorylation was detected in con-
trol animals, however a signiﬁcant increase was observed in
animals pretreated with GH (Fig. 5 upper panels). JNK phos-
phorylation was reduced by 65–80% in rats pretreated with
GH plus aspirin. Consistent with JNK activation, c-Jun phos-
phorylation was induced by GH treatment and reversed by
aspirin in a similar fashion to JNK activity (Fig. 5 middle pan-
els). GH treatment induced SOCS 3 expression in liver, muscle
and WAT, however pretreatment with aspirin did not change
the modulation in SOCS 3 expression by GH in these tissues.4. Discussion
Studies in humans and animal models show that chronic GH
excess has an anti-insulin eﬀect on carbohydrate and lipid
metabolism [6]. In this study, we demonstrate that pretreat-
ment with aspirin inhibits GH-induced insulin resistance.
GH was observed to lead to serine phosphorylation of IRS-1
and aspirin reversed this phenomenon in liver, muscle and
WAT, in parallel with a reduction in JNK activity. In addition,
our data show an impairment in insulin activation of IR, IRS-
1 and IRS-2 tyrosine phosphorylation and IRS-1/PI 3-K and
IRS-2/PI3-K associations in rats chronically treated with GH
and, consistent with the reduction of IRS-1 serine phosphory-
lation observed in animals pretreated with aspirin and GH,
there was an increase in IRS-1 protein levels and tyrosine
phosphorylation.
There are a number of possible mechanisms that may lead to
an impairment of the insulin-signaling pathway in GH-chron-
ically treated rats. Our results show that increased serine phos-
phorylation of IRS-1 may be one of these mechanisms. Our
results also show that GH treatment induced the expression
of SOCS3, pointing to another possible mechanism GH-
induced insulin resistance. Previous studies demonstrated thatoverexpression of SOCS3 decreases insulin-induced IRS-1 and
IRS-2 tyrosine phosphorylation levels, inducing insulin resis-
tance [22]. However, this modulation of SOCS3 by GH was
not reversed by aspirin.
Serine phosphorylation of IRS proteins is believed to be a
major mechanism of suppression of IRS-1/2 activity that con-
tributes to insulin resistance [23,24]. Regulation of serine phos-
phorylation of IR and IRS-1/2 proteins has been one of the
focuses in the search for the molecular mechanism of insulin
resistance. The reduction in IRS-1 protein levels in the liver,
muscle and WAT of GH-treated rats may also contribute to
the insulin resistance observed in these animals, since the de-
crease in IRS-1 tyrosine phosphorylation is probably due to
the diminished IRS-1 expression. These reductions in IRS-1
protein expression may be secondary to the increased degrada-
tion of these proteins, such as the consequence of increased ser-
ine phosphorylation levels [25], and/or may be under
transcriptional control. In contrast, the protein levels of IRS-
2 remained unaltered in the presence of GH. A recent report
demonstrated that hyperinsulinemia mediates reductions of
IRS-1/2 protein expression via diﬀerent mechanisms[26]. It is
possible that in GH-induced insulin resistance in animals,
which has also hyperinsulinemia, diﬀerent mechanisms of IRSs
degradation may be operating to explain the diﬀerences in pro-
tein expression observed. Diﬀerences in IRS-1 or IRS-2 protein
expression may have a role in tissue speciﬁc insulin resistance,
since IRS-1 has a more important role in mediating insulin sig-
naling in muscle and IRS-2 in liver [27]. However, the insulin
induced tyrosine phosphorylation levels of these proteins and
interaction with p85 were similarly altered in the liver and mus-
cle of GH-treated animals. In accordance, functional studies
demonstrated that elevated GH levels induces insulin resis-
tance in liver and muscle [28,29].
Three recent studies provide clear evidence that aspirin pro-
motes peripheral glucose disposal by enhancing insulin sensi-
tivity [21,30,31]. In these studies, aspirin was found to
increase insulin-stimulated glucose uptake and to reduce serine
phosphorylation of IRS-1. Our results show a marked reduc-
tion in IRS-1 serine phosphorylation after aspirin treatment
in GH-treated rats in parallel with an increase in IR autophos-
phorylation. A previous study demonstrated that treatment of
cultured murine adipocytes with TNF-a induces serine phos-
phorylation of insulin receptor substrate 1 (IRS-1) and con-
verts IRS-1 into an inhibitor of the IR tyrosine kinase
activity in vitro [32]. The IRS-1-mediated inhibition of IR
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actions between the IR and IRS-1 [33,34]. Serine-phosphory-
lated IRS-1 might associate with the IR to block the
autophosphorylation reaction, alternatively, serine phosphory-
lated IRS-1 might act indirectly on the IR through an associ-
ation with an inhibitor that acts on the IR in a stoichometric
or catalytic fashion [32].
Taken together, these data suggest that GH mediates insulin
resistance, at least in part, by inducing IRS-1 serine phosphor-
ylation and decreasing IRS-1/2 tyrosine phosphorylation and
that this eﬀect is inhibited by aspirin. Since the IR/IRS-1/2
pathway is involved in glucose uptake in adipocytes and mus-
cle and glycogen synthesis in liver and muscle we may suggest
that aspirin, by acting on this pathway reverses insulin resis-
tance of animals treated with GH.
In previous studies from our laboratory, GH treatment did
not decrease IR tyrosine phosphorylation in rat liver nor
IRS-1 expression in muscles [7]. The reasons for these discrep-
ancies are not clear, but may be related to methodological dif-
ferences in the duration of GH treatment.
JNK is a serine kinase that is responsible for activation of
the transcription factors, c-Jun and ATF2, by phosphorylating
these two proteins [35,36]. Recently, JNK has been linked to
the regulation of insulin signaling by several studies
[9,12,15,37,38]. It is suggested that JNK contributes to insulin
resistance by phosphorylating IRS-1 at serine 307, and this
phosphorylation leads to inhibition of the IRS-1 function
[9,15,37,38]. It has recently been observed that aspirin inhibits
JNK activity [17,18]. In this study, we observed that aspirin
inhibited GH-induced JNK activity, and that this inhibition
was accompanied by a reduction in IRS-1 serine phosphoryla-
tion at Ser307, indicating that this serine kinase is one of the
causes of GH-induced insulin resistance.
In summary, aspirin pretreatment improves insulin sensitiv-
ity in GH-treated rats by reversing GH-induced decreases in
insulin-stimulated IR, IRS-1 and IRS-2 tyrosine phosphoryla-
tion, and also IRS-1 protein expression. The eﬀect of aspirin
on insulin action is further supported by our ﬁndings that rats
pretreated with aspirin show a reduction in IRS-1 serine phos-
phorylation and are also protected from GH-induced insulin
resistance. Overall, these results provide important new in-
sights into the mechanism of GH-induced insulin resistance.
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